EA201290852A1 - Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель - Google Patents
Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилительInfo
- Publication number
- EA201290852A1 EA201290852A1 EA201290852A EA201290852A EA201290852A1 EA 201290852 A1 EA201290852 A1 EA 201290852A1 EA 201290852 A EA201290852 A EA 201290852A EA 201290852 A EA201290852 A EA 201290852A EA 201290852 A1 EA201290852 A1 EA 201290852A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hiv
- ccr5
- protease inhibitor
- pharmacokinetic
- amplifier
- Prior art date
Links
- 229940126544 HIV-1 protease inhibitor Drugs 0.000 title abstract 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title abstract 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 2
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 206010038997 Retroviral infections Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000001228 trophic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение раскрывает новую комбинированную терапию для лечения ВИЧ-1, основанную на комбинации по меньшей мере одного антагониста CCR5, по меньшей мере одного ингибитора протеазы ВИЧ-1 и по меньшей мере одного фармакокинетического усилителя указанного по меньшей мере одного антагониста CCR5 и/или по меньшей мере одного ингибитора протеазы ВИЧ-1. Комбинация предназначена для применения в пероральном лечении расстройства, выбранного из группы, состоящей из ВИЧ-1 инфекции, ретровирусных инфекций, генетически связанных с ВИЧ, и СПИД, у ранее не получавшего лечения пациента, инфицированного CCR5-трофным вирусом ВИЧ-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32042810P | 2010-04-02 | 2010-04-02 | |
PCT/IB2011/051370 WO2011121558A1 (en) | 2010-04-02 | 2011-03-30 | Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201290852A1 true EA201290852A1 (ru) | 2013-04-30 |
Family
ID=44227938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201290852A EA201290852A1 (ru) | 2010-04-02 | 2011-03-30 | Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель |
Country Status (19)
Country | Link |
---|---|
US (1) | US20130023496A1 (ru) |
EP (1) | EP2552429A1 (ru) |
JP (1) | JP2013523716A (ru) |
KR (1) | KR20130025899A (ru) |
CN (1) | CN102905698A (ru) |
AU (1) | AU2011234013A1 (ru) |
BR (1) | BR112012024522A2 (ru) |
CA (1) | CA2794443A1 (ru) |
CL (1) | CL2012002743A1 (ru) |
CO (1) | CO6630124A2 (ru) |
CR (1) | CR20120558A (ru) |
DO (1) | DOP2012000253A (ru) |
EA (1) | EA201290852A1 (ru) |
MA (1) | MA34215B1 (ru) |
MX (1) | MX2012011415A (ru) |
PE (1) | PE20130529A1 (ru) |
SG (1) | SG184176A1 (ru) |
WO (1) | WO2011121558A1 (ru) |
ZA (1) | ZA201207214B (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003014105A1 (en) | 2001-08-08 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use as hiv inhibitors |
SG10201708595YA (en) * | 2013-05-15 | 2017-11-29 | Tobira Therapeutics Inc | Cenicriviroc compositions and methods of making and using the same |
BR112017004708A2 (pt) * | 2014-09-12 | 2017-12-05 | Tobira Therapeutics Inc | terapia de combinação de cenicriviroc para o tratamento de fibrose |
US11292785B2 (en) | 2018-02-02 | 2022-04-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof |
WO2022223007A1 (zh) * | 2021-04-23 | 2022-10-27 | 中国人民解放军军事科学院军事医学研究院 | 抗病毒多肽化合物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1208397A (en) | 1995-12-28 | 1997-07-28 | Takeda Chemical Industries Ltd. | Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists |
JP2000516210A (ja) | 1996-07-12 | 2000-12-05 | ロイコサイト,インコーポレーテッド | ケモカインレセプターアンタゴニストとその使用方法 |
US6140338A (en) | 1996-07-29 | 2000-10-31 | Banyu Pharmaceutical, Co., Ltd. | Chemokine receptor antagonists |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
AU5803398A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
WO1998025604A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
US6166006A (en) | 1997-12-19 | 2000-12-26 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
US6147095A (en) * | 1998-11-04 | 2000-11-14 | Pharmacia & Upjohn Company | Method for improving the pharmacokinetics of tipranavir |
PE20001420A1 (es) | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
PE20010628A1 (es) | 1999-10-01 | 2001-06-18 | Takeda Chemical Industries Ltd | Compuestos de amina ciclica, su produccion y su uso |
HU225810B1 (en) | 2000-05-26 | 2007-10-29 | Pfizer | Therapeutically effective tropane derivatives, process for their preparation pharmaceutical compositions containing them and their use |
WO2003014105A1 (en) | 2001-08-08 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use as hiv inhibitors |
EP1420799B1 (en) * | 2001-08-31 | 2006-10-04 | Bristol-Myers Squibb Company | Use of atazanavir in hiv therapy |
PL372968A1 (en) | 2002-04-08 | 2005-08-08 | Pfizer Inc. | Tropane derivatives as ccr5 modulators |
ES2295924T3 (es) | 2003-10-03 | 2008-04-16 | Pfizer, Inc. | Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion. |
CN101495145A (zh) * | 2005-07-22 | 2009-07-29 | 原基因药物有限公司 | 用于减少受hiv-1感染的患者中病毒负荷的方法 |
ES2438019T3 (es) * | 2005-07-22 | 2014-01-15 | Cytodyn, Inc. | Procedimientos para reducir la carga viral en pacientes infectados por el VIH-1 |
-
2011
- 2011-03-30 MA MA35343A patent/MA34215B1/fr unknown
- 2011-03-30 EP EP11715752A patent/EP2552429A1/en not_active Withdrawn
- 2011-03-30 JP JP2013502021A patent/JP2013523716A/ja not_active Withdrawn
- 2011-03-30 SG SG2012069902A patent/SG184176A1/en unknown
- 2011-03-30 MX MX2012011415A patent/MX2012011415A/es unknown
- 2011-03-30 US US13/638,999 patent/US20130023496A1/en not_active Abandoned
- 2011-03-30 BR BR112012024522A patent/BR112012024522A2/pt not_active IP Right Cessation
- 2011-03-30 KR KR1020127028919A patent/KR20130025899A/ko not_active Application Discontinuation
- 2011-03-30 EA EA201290852A patent/EA201290852A1/ru unknown
- 2011-03-30 CN CN2011800269953A patent/CN102905698A/zh active Pending
- 2011-03-30 CA CA2794443A patent/CA2794443A1/en not_active Abandoned
- 2011-03-30 AU AU2011234013A patent/AU2011234013A1/en not_active Abandoned
- 2011-03-30 PE PE2012001826A patent/PE20130529A1/es not_active Application Discontinuation
- 2011-03-30 WO PCT/IB2011/051370 patent/WO2011121558A1/en active Application Filing
-
2012
- 2012-09-26 ZA ZA2012/07214A patent/ZA201207214B/en unknown
- 2012-09-27 DO DO2012000253A patent/DOP2012000253A/es unknown
- 2012-09-28 CO CO12170763A patent/CO6630124A2/es not_active Application Discontinuation
- 2012-09-28 CL CL2012002743A patent/CL2012002743A1/es unknown
- 2012-11-01 CR CR20120558A patent/CR20120558A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR20120558A (es) | 2013-04-09 |
CA2794443A1 (en) | 2011-10-06 |
US20130023496A1 (en) | 2013-01-24 |
PE20130529A1 (es) | 2013-05-14 |
MX2012011415A (es) | 2013-02-26 |
KR20130025899A (ko) | 2013-03-12 |
CO6630124A2 (es) | 2013-03-01 |
AU2011234013A1 (en) | 2012-11-15 |
CN102905698A (zh) | 2013-01-30 |
SG184176A1 (en) | 2012-10-30 |
EP2552429A1 (en) | 2013-02-06 |
MA34215B1 (fr) | 2013-05-02 |
CL2012002743A1 (es) | 2012-12-14 |
ZA201207214B (en) | 2014-03-26 |
BR112012024522A2 (pt) | 2017-08-08 |
DOP2012000253A (es) | 2012-12-31 |
WO2011121558A1 (en) | 2011-10-06 |
JP2013523716A (ja) | 2013-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120457T1 (el) | Αντι-ιικη θεραπεια | |
CY1118774T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης | |
MX2020006864A (es) | Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides. | |
UA103881C2 (ru) | Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека | |
EA201001508A1 (ru) | Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич | |
EA201391108A1 (ru) | Лечение липодистрофии | |
EA201301158A1 (ru) | Противовирусные соединения | |
TR201909152T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımı. | |
EA201890236A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
MX2013005478A (es) | Compuestos heterociclicos condensados antivirales. | |
MX2017010506A (es) | Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. | |
EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
EA201300135A1 (ru) | Комбинированная фармацевтическая композиция и способы лечения и профилактики инфекционных заболеваний | |
EA202190854A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
EA201290852A1 (ru) | Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель | |
EA201171186A1 (ru) | Сокристалл этравирина и никотинамида | |
WO2016086153A3 (en) | Use of hsp90 inhibitors for the treatment of hiv infections and aids | |
WO2008154246A8 (en) | Hiv integrase inhibitors | |
EA201390452A1 (ru) | Вакцина | |
TR201110202A2 (tr) | Hepatit B ve/veya AIDS tedavisinde antiretroviral farmasötikler. | |
EA201900586A1 (ru) | Комбинированный лекарственный препарат для терапии вирусных инфекций | |
EA201990295A1 (ru) | Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич | |
PL401956A1 (pl) | Pochodne 1,2,4-triazolo-5-tionu oraz ich zastosowanie | |
WO2008104857A3 (en) | Method for predicting susceptibility of hiv infection | |
UA103880C2 (ru) | Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека |